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Abstract 
Objective: To establish if harvesting cartilage to source chondrocytes for autologous 
chondrocyte implantation (ACI) results in donor-site morbidity. 
Design: Twenty-three patients underwent ACI for chondral defects of either the ankle or the 
hip.  This involved cartilage harvest from the knee (stage I), chondrocyte expansion in the 
laboratory and implantation surgery (stage II) into the affected joint.  Prior to chondral 
harvest, no patient had sought treatment for their knee.  Lysholm knee scores were 
completed prior to chondral harvest and annually post-ACI.  Histological analyses of the 
donor site were performed at 12.3±1.5 months for 3 additional patients who had previously 
had ACI of the knee.  
Results:  The median pre-operative Lysholm score was 100, with no significant differences 
observed at either 13.7±1.7 months or 4.8±1.8 years post-harvest (median Lysholm scores 
91.7 and 87.5, respectively).  Patients whose cartilage was harvested from the central or 
medial trochlea had a significantly higher median Lysholm score at latest follow-up (97.9 and 
93.4 respectively), compared with those taken from the intercondylar notch (median Lysholm 
score 66.7).  The mean ICRS II histological score for the biopsies taken from the donor site 
of three additional knee ACI patients was 117+/-10 (maximum score 140).  
Conclusions: This study suggests that the chondral harvest site in ACI is not associated 
with significant joint morbidity, at least up to 5 years post-harvest.  However, one should 
carefully consider the location for chondral harvest as this has been shown to affect knee 
function in the longer term.     
 
Keywords: Autologous Chondrocyte Implantation; Cartilage repair; donor-site morbidity; 
osteoarthritis; histology  
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Introduction 
 
Chondral and osteochondral lesions in the hyaline cartilage of an articulating joint often 
require surgical intervention due to the limited ability of cartilage self-repair.  Many 
techniques to restore articular cartilage and joint function have been established over the 
years, including mosaicplasty, osteochondral autograft transport system (OATS) and 
autologous chondrocyte implantation (ACI).  Mosaicplasty and OATS involve obtaining 
cylindrical osteochondral grafts of varying sizes from the lesser loaded areas of the articular 
surface of the donor joint and implanting them into the recipient osteochondral lesion.  
Traditionally, mosaicplasty requires multiple small osteochondral grafts (typically 3-8mm)1-3 
whereas OATS usually requires one single large defect-sized graft (typically ~10mm)4 and 
either procedure can be performed in a single operation.  ACI on the other hand is a two-
stage procedure, requiring a chondral harvest of macroscopically healthy cartilage, also from 
a lesser loaded area of the joint (stage I) and subsequent chondrocyte isolation, culture and 
proliferation.  The resulting cells are then implanted into the defect (stage II) approximately 
3-4 weeks later,5 beneath either a periosteal or collagen membrane such as ChondroGide®. 
 
Originally developed to treat chondral lesions in the knee,5 ACI has since been adapted for 
the treatment of chondral defects in other joints such as the ankle6-9 and less commonly, the 
hip.10-13  Whilst encouraging results in terms of cartilage growth and improvement of joint 
function in the treated joint have been reported, little has been published on the potential 
morbidity caused by harvesting healthy tissue from the joint in ACI.  What has been 
described regarding donor-site morbidity in the literature to date predominantly relates to 
osteochondral harvest for mosaicplasty3 or OATS4,14 which has obvious differences in 
potential issues for donor-site morbidity than solely a chondral harvest due to the depth and 
size of the harvest taken.  Donor-site morbidity is an understandable concern as the integrity 
of the healthy, intact hyaline cartilage is violated. 
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In this study we aimed to assess the effect of chondral harvest on knee function by looking 
at a small population of patients who had ACI treatment of either the ankle or the hip but with 
a chondral harvest obtained from the knee.  This group of patients therefore provide a 
unique opportunity to assess the effect of controlled chondral injury on knee function.  We 
have also analysed the repair tissue formed at the donor site from 3 additional patients who 
previously underwent ACI for the knee.  
 
Method and Materials 
 
Ankle and hip ACI patients 
 
Patients and surgical technique 
 
Between 1998 and 2009, 23 patients (16 males, 7 females; mean age 38.4±10.1 years, 
range 17.2-61.3) underwent ACI treatment for chondral defects of the ankle (n=19) and hip 
(n=4), respectively.  The average defect size treated was 2.1±1.6cm2 (range, 0.5 to 7.8).  
ACI surgery involved chondrocyte harvest at the knee (stage I) from the ispilateral side in 21 
patients and the contralateral side for 1 ankle and 1 hip patient, followed by chondrocyte 
implantation surgery (stage II).  Chondral harvest was performed arthroscopically through 
standard anterolateral and anteromedial portals under tourniquet control.  Specimens of 
cartilage (mean weight 271.9±97.6mg, range 103 to 520) were taken using a 5mm gouge 
from a region of the knee with low weight-bearing status.  The biopsy site locations were 
recorded and the biopsy material was transported to our on-site Good Manufacturing 
Practice (GMP) standard ‘Oscell’ cell manufacturing facility for chondrocyte culture.  Ten 
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samples were taken from the central trochlea (mean age 36.0±14.0 years, range 17.2 to 
61.3), 2 from the lateral trochlea (mean age 44.6±1.6 years, range 43.5 to 45.8), 6 from the 
medial trochlea (mean age 40.7±5.6 years, range 31.9 to 47.2) and 5 from the intercondylar 
notch (mean age 38.0±6.1 years, range 28.3 to 44.3).  A mean yield of 5.2x105±1.3x105 
(range 3x105 to 8x105) chondrocytes were obtained from the harvest biopsy.  Following cell 
culture, a mean of 4.9x106±1.9x106 chondrocytes (range 1.3x106 to 8x106) were implanted 
into the treatment site approximately 3 weeks later under either a periosteal (n=20) or 
ChondroGide® (n=3) patch.  One ankle patient required a follow-up knee arthroscopy 1.4 
years post-harvest. Patients in this study have been investigated as part of an ethically 
approved project (REACT 09/H1203/90, granted by West Midlands National Research 
Ethics Service).   
 
Prior to chondral harvest, no patient had sought treatment for their knee.  Modified Lysholm 
scores, a measure of knee function,15 were completed pre-operatively and at yearly intervals 
post-cell implantation.  Lysholm scores were categorized as excellent (95–100), good (84–
94), fair (65–83) or poor (≤64).16    
  
Statistical analysis  
 
A post-hoc power analysis demonstrated a power of 0.8, at a significance level of 5% 
(p=0.05) to identify a Lysholm score difference of 13 points19, indicating that this study would 
require a paired sample of at least 10 patients.  Data were tested for normality using the 
Shapiro-Wilk normality test.  Non-parametric paired data (Lysholm scores) were analysed for 
statistical differences with the Wilcoxon signed-rank test.  Non-parametric un-paired data 
were analysed for statistical differences using the Mann-Whitney U Test.  Correlations were 
tested for using a Spearman’s Rank correlation.  Statistical differences between grouped 
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frequency data of the Lysholm Score parameters were tested for using a Chi-squared test of 
independence.  A p-value of <0.05 was deemed significant.  All statistical analyses were 
performed using the software programme Analyse-it Software Ltd, Leeds, UK. 
 
Additional Donor Site Study from Three Knee ACI Patients 
 
Histology  
 
Three additional patients, who had received ACI treatment for chondral defects in their 
knees, underwent a follow-up arthroscopy at 12.3±1.5 months, with full informed consent.  
The donor site was examined and core biopsies of the repair tissue formed were obtained.  
These were snap-frozen in liquid nitrogen-cooled hexane prior to sectioning and 7µm thick 
cryosections were collected onto poly-L-lysine coated slides.  Sections were stained with 
either haematoxylin and eosin (H&E) or toluidine blue (TB) and viewed with bright light 
microscopy to assess the general morphology and proteoglycan content of the repair tissue, 
respectively.  Sections were also viewed under polarised light to determine collagen fibril 
orientation to distinguish between hyaline cartilage and fibrocartilage morphologies.  
Sections were scored using both the ICRS II17 (maximum score 140) and the OsScore18 
(maximum score 10) scoring systems, where a higher score for either systems represents a 
better quality of repair tissue.      
 
Immunohistochemistry 
 
In addition, immunohistochemistry for collagen types I and II was undertaken; for this 
cryosections were incubated with hyaluronidase prior to fixing in 4% formaldehyde.  
 7 
Antibodies against collagen type I (1:500, clone I-8H5, MP Biomedicals, Cambridge) or type 
II (1:10, clone CIIC1, Developmental Studies Hybridoma Bank, Iowa) were incubated for 60 
minutes prior to the secondary goat anti-mouse biotinylated antibody for 60 minuntes 
(Vectastain Elite ABC kit, Vector Laboratories, Peterborough).  Adjacent sections were 
stained with an isotype-matched murine IgG1 (Dako, Cambridge) as a negative control.  
Non-specific binding and endogenous peroxidase activity were blocked using normal goat 
serum in 3% bovine serum albumin and 0.3% hydrogen peroxide in methanol respectively.  
Sections were washed three times with PBS between steps and all steps were performed at 
room temperature.  Labelling was enhanced with streptavidin-peroxidase (Vectastain Elite 
ABC kit, Vector Laboratories, Peterborough) and visualised with diaminobenzadine (DAB).   
 
 
Results 
Ankle and hip ACI patients 
 
At a mean of 5.1±8.5 days pre-operatively (range 0-31 days), the median Lysholm score for 
all patients was 100 (IQR 8.7).  Median Lysholm scores at the first annual review (13.7±1.7 
months post-harvest, range 12 to 18.3 months) and at 4.8±1.8 years post-harvest (range 1.2 
to 7.8, termed “latest follow-up” from here on) were 91.7 (IQR 12.5) and 87.5 (IQR 22.2), 
respectively.  Neither the first annual review nor the latest follow-up scores resulted in 
significantly different scores to the pre-operative scores (Figure 1A).  The majority of patients 
were classified as having either an excellent or good Lysholm score at all three time points 
(Table 1).  At latest follow-up, the median Lysholm score of the opposite knee was 100 (IQR 
5.3) and significantly higher than the harvest knee (p=0.0046).  Women had a greater 
change in median score from the pre-operative score compared to men at both the first 
annual follow up (median change -4.2 and 0, respectively) and the latest follow-up (median 
 8 
change -16.7 and 0, respectively), but neither were significant, either between the time 
points or between the sexes.   
 
At the first annual review, Lysholm scores had decreased from pre-operative scores in 44% 
of patients, increased in 25% and remained the same in 31% of patients.  The median 
change in Lysholm score from pre-operative to first annual review was 0.  By the latest 
follow-up, Lysholm scores had decreased from pre-operative scores in 56% of patients, 
increased in 13% and remained the same in 31% of patients.  The median change in 
Lysholm score from pre-operative to latest follow-up was -4.2 (Figure 1B).  From the 
Lysholm score, a significantly increased occurrence of pain was reported by patients at the 
latest follow-up compared to pre-operatively (p=0.05, Figure 2).  In addition, significantly 
more catching and locking sensations were reported by patients at both the first annual 
review and latest follow-up (p=0.004 and p=0.019 respectively, Figure 2).  Only 3 patients 
reported swelling of their knee.  One patient reported a constantly swollen knee at the first 
annual review, but no swelling 6.3 years post-harvest at latest follow-up.  Two patients 
reported swelling only upon severe exertion at 7.8 and 6.1 years follow-up.  
 
The influence of the location of the chondral harvest was considered; there was no 
significant difference between the mean ages of each harvest location group.  The pre-
operative Lysholm score for harvests obtained from the central trochlea was 97.6 and 100 
for both the medial trochlea and the intercondylar notch (Figure 3A), with no significant 
differences in scores between the different harvest locations.  At the first annual review, 
median Lysholm scores were lower, but not significantly, than pre-operative scores for all 
regions; 87.5, 95.8 and 91.7 for the central trochlea, medial trochlea and intercondylar notch, 
respectively (Figure 3B).  By the latest follow-up, Lysholm scores for the central trochlea had 
returned to pre-operative levels (median 97.9, mean follow-up 5.5±0.9 years, range 4 to 6.5 
years).  Lysholm scores for the medial trochlea group at the latest follow-up were maintained 
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at 93.4 with a mean follow-up of 4.9±1.6 years (range 3.4 to 7.8 years), whilst for the 
intercondylar notch group, the median Lysholm score was 66.7 with a mean follow up of 
2.9±2.1 years (range 1.2 to 6.1 years).  These were significantly lower than for both the 
central and medial trochlea groups (p=0.01 and 0.02, respectively, Figure 3C).  The two 
patients who had a chondral harvest from the lateral trochlea, had pre-operative Lysholm 
scores of 87.5 and 100, first annual review scores of 70.8 and 100 and latest follow-up 
scores of 79.2 and 75. 
 
There was no significant relationship between the site of chondral harvest and the weight of 
harvest taken (p=0.33) or the Lysholm score at either first annual review or latest follow-up 
(p=0.996 and p=0.148 respectively).  Patient’s age at ACI was also found not to correlate 
with either the pre-operative or latest follow-up Lysholm scores (p=0.59 and p=0.12 
respectively), nor were there any significant differences in either the first annual review or 
follow-up Lysholm scores between the sexes.   
 
One patient in the series required a further knee arthroscopy 1.4 years post-harvest after 
complaining of clicking and grinding behind the patella and reporting a Lysholm score of 68.  
At the stage I arthroscopy, this patient was noted by the surgeon to have a small Grade III 
chondral defect on the trochlea; at this follow-up arthroscopy this defect was observed to be 
larger and was subsequently debrided.  The chondral harvest site on the lateral trochlea was 
found to have healed with a good level of fill and with good integration with the surrounding 
native articular cartilage, but had a softer consistency.  There were also some fronds present 
here, which were debrided.  Five years post-arthroscopy, this patient now reports a Lysholm 
score of 91.   
 
Additional Donor Site Study 
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All 3 donor sites of the patients who underwent a follow-up arthroscopy following ACI of the 
knee, were seen by the surgeon to be well healed with smooth, white cartilage that appeared 
to be well integrated into the surrounding native hyaline cartilage (Figure 4).  The core 
biopsies obtained were full depth (Figure 5A) with generally good matrix metachromasia 
(Figure 5B).  Under polarised light, one biopsy was observed to be hyaline cartilage and the 
other 2 biopsies were a mixture of both hyaline cartilage and fibrocartilage, the hyaline 
cartilage being at the base of the biopsy in both cases and well integrated into both the 
underlying subchondral bone and the upper fibrocartilaginous portion (Figure 5C-D).  All 3 
biopsies had moderately good surface architecture (Figure 5E) and generally good cell 
morphology with most cells being rounded and of a chondrocytic appearance.  The mean 
ICRS II and OsScore histological scores for the biopsies taken from the donor site were 
116.8+/-10 and 8.7±0.8 respectively.  Immunohistochemical staining for collagen type I was 
detected throughout the full depth of the biopsies (Fig 5F), whereas collagen type II was 
predominantly restricted to the hyaline portions of the biopsies, but could also be detected to 
a lesser amount in the fibrocartilaginous portions adjacent to and above this (Fig 5G). 
 
Discussion 
 
ACI has been used since 19945 as treatment for cartilage defects with good long-term 
results.20,21  Little is known, however, of the effect of the chondral injury needed to source the 
chondrocytes for ACI on knee function.  There are many reports on the use of osteochondral 
grafting for locations such as the ankle, where the donor site has been the knee; a few of 
these studies make reference to donor-site morbidity,1-4,6,8,14,22-25 but often is not a focussed 
outcome of the study.  Chondral harvest from the knee for the treatment of the ankle is rarely 
performed nowadays as most chondral harvests are taken from the joint to be treated7,9,26 for 
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various reasons, including restricting surgical trauma to a second joint and both anatomical 
and biomechanical differences between knee and ankle cartilage.27  A recent study has also 
demonstrated that chondrocytes extracted from the margins of both grade III and IV 
osteochondral lesions in the knee are comparable to those from non-weight bearing areas of 
the joint currently used for chondral harvest.28  Adopting this type of approach would 
eliminate any potential for donor-site morbidity, but there are no long-term clinical data on 
the outcome of the use of debrided edge cartilage as a source of autologous chondrocytes. 
 
To our knowledge, our study is the first to look at the effects of chondral harvest alone on 
knee function.  We found that following a biopsy of approximately 270mg of cartilage from 
the knee, the majority of patients maintained a good or excellent Lysholm score.  Scores at 
13.7 months post-harvest were not significantly different to pre-operative scores and were 
maintained at 4.8 years follow up.  Although our study did not assess the area of chondral 
harvest, we did record the mass of the tissue harvested and we did not find a significant 
correlation between it and change in knee function.  In addition, we found no correlation 
between either the patient’s age or sex and knee function.  
 
It is also worth noting that whilst none of the patients in our study had previously sought 
treatment for their knees prior to harvest, the pre-operative Lysholm scores were not all 100, 
with some as low as 62.5 (where scores less than 83 are considered “fair” and scores less 
than 64 are considered “poor”).16  Two patients who received ACI for chondral defects in the 
hip, reported low pre-operative Lysholm scores, which could be attributed to referred pain 
from the hip,29 particularly as the Lysholm score increased dramatically at the first annual 
review.  This demonstrates how patient perception and clinical observation differ and do not 
always correlate; it also highlights the importance of comparing the difference in knee scores 
from pre- to post-operative rather than the post-operative score in isolation.  Likewise, a 
reduced Lysholm score at the latest follow-up could possibly be due to either existing or 
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newly developed degenerative changes within the joint and not actually related to the donor-
site.  However, our results demonstrate that the median Lysholm score at latest follow-up for 
the opposite knee to which the harvest was taken was significantly greater than the harvest 
knee, despite both knees having a median Lysholm score of 100 pre-operatively.  This, we 
believe, is a reflection on the spread of the data and the limited number of patients in this 
study.  Indeed, some studies have refrained from using the Lysholm score as a measure of 
knee function when analysing the effect of an osteochondral harvest for ankle mosaicplasty, 
as they believe that the score may be biased by the painful and functionally reduced 
ipsilateral ankle joint and hence mask the true knee score.25  We respect that the Lysholm 
score is not, in everyone’s opinion, the best score to use and there are several other scores 
that are also validated which are frequently used.  However, the scores used in the present 
study are historical, some being collected up to 17 years ago when only Lysholm scores 
were collected.  Despite this, the Lysholm score is recognised as a reliable measure for use 
in patients with chondral injuries.30   
     
The first ACI procedures reported harvesting cartilage from “a minor load-bearing area of the 
upper medial femoral condyle”.5  One would assume this was to limit potential donor-site 
morbidity, although this particular rationale was not mentioned.  A study using a 
biomechanical cadaveric model demonstrated the lowest contact pressures in the knee to be 
on the medial trochlea and thus recommended this location for future procedures requiring 
an osteochondral harvest to minimise donor site morbidity.31  Garretson et al.,31 also suggest 
the “worse” place for an osteochondral harvest to be the central trochlea, due to having the 
highest contact pressures.  Interestingly, in our study, we found patients who had a harvest 
obtained from either the central or the medial trochlea had significantly better Lysholm 
scores at latest follow-up than those where the harvest was taken from the intercondylar 
notch.  Garretson’s study did not include the intercondylar notch.  Unfortunately, we were 
unable to statistically compare the effect of a chondral harvest from the lateral trochlea with 
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the other locations included in this study due to lack of patients within this category, but, at 
the latest follow-up, both patients only had a “fair” Lysholm score indicating the lateral 
trochlea to be a less than optimal harvest location.  However, the small number of patients 
involved in the study (n=25) and even fewer numbers for individual locations (n=2-10) is 
obviously a limiting factor in being able to make any statistically supported recommendations 
for an optimal location for chondral harvest.   
 
It is difficult to make a direct comparison of donor-site morbidity between osteochondral and 
chondral harvests due to the difference in the size of harvest, the types of tissue removed 
and the resulting defect created.  One could speculate that perhaps an osteochondral 
harvest may in fact have an improved healing potential since they extend beyond the 
subchondral bone and thus encourage bleeding and entry of bone-marrow stromal cells into 
the donor-site, which may contribute to the repair process, much in the way that a standard 
microfracture procedure works.  A chondral harvest, however, does not extend into the 
subchondral bone and so there is no such response stimulated.  On the other hand, only one 
donor site is required for a chondral harvest for ACI, whereas procedures like mosaicplasty 
often result in multiple donor sites and have a greater overall donor area.  Large areas of 
OATS harvests have previously been reported to correlate with a poorer Lysholm score at 
final follow-up.4     
 
Macroscopically, all 4 donor-sites (1 from knee harvest for ankle ACI and 3 from knee ACI 
patients) observed by arthroscopy in our study were found to have healed with good 
integration into the surrounding cartilage.  One donor-site in particular, that was noted to be 
of a softer consistency than the surrounding cartilage, could indicate the presence of a 
fibrocartilaginous-like tissue rather than a hyaline-like tissue.  Microscopic examination of 3 
repair tissue biopsies revealed 2 were a mixture of both hyaline cartilage and fibrocartilage 
whilst the other was solely hyaline cartilage. Previous studies have reported that following an 
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osteochondral harvest, the donor site fills with a fibrocartilaginous tissue.1  It is possible that 
the hyaline cartilage observed microscopically, or at least some of it, could be residual native 
hyaline cartilage due to the nature of the gouge instrument used to harvest the initial 
cartilage for Stage 1 and the “U-shape” of the defect left behind.  However, there is evidence 
that the repair tissue formed at the treatment site following ACI matures with time32,33 and so 
maturation of the tissue formed in the donor-site may also occur.   
 
In conclusion, our study demonstrates that at a mean of 4.8 years following chondral harvest 
for ACI treatment, there was no significant change in median Lysholm knee scores 
compared to pre-operative scores.  These results suggest that there is no significant 
harvest-site morbidity of the knee associated with harvesting cells for use in ACI, particularly 
when taken from the central or medial trochlea.  Some patients, however, did report greater 
pain, catching and locking at their final follow-up, though whether this was due to donor-site 
morbidity per se or injury or degeneration during the average 4.8 year post-harvest follow-up 
time, is not possible to differentiate.  However, one should carefully consider the location for 
chondral harvest as this has been shown to affect knee function long-term.  It is 
recommended that patients should be made aware that they may experience some 
functional deficit, which is likely to be transient.  It is also vital that pre-operative knee scores 
are measured, as patients who rate their knees as asymptomatic may have lower knee 
scores than the surgeon assumes.  Whilst this study demonstrates no significant donor-site 
morbidity and good healing of the chondral harvest site both macroscopically and 
microscopically, more in-depth studies with a larger cohort of patients are required to fully 
assess the effect of harvest location on knee function and both the in-vivo appearance and 
the histological quality of the repair tissue formed within the donor site to fully assess donor-
site morbidity and understand the processes involved in what appears to be spontaneous 
cartilage regeneration.   
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Figure Legends 
Figure 1 
Box and whisker plots displaying A) Lysholm scores for the following time points: pre-
operative, 13.7±1.7 months post-harvest (first annual review) and at 4.8±1.8 years post-
harvest (latest follow-up) and B) median difference in Lysholm scores at the first annual 
review and latest follow-up compared with pre-operative scores.  Lysholm scores at the first 
annual review (median 91.7) and at latest follow up (median 87.5) were not significantly 
different to pre-operative scores and neither was the difference in Lysholm score.  The box 
and the horizontal line represent the interquartile range (IQR) and the median respectively.  
Outliers are represented as a small triangle. 
 
Figure 2 
Histograms depicting the 7 different scoring parameters of the modified Lysholm score13 and 
the percentage of patients within each category pre-operatively (dark grey bar), at the first 
annual review (light grey bar) and the latest follow-up (white bar).  A significantly higher 
occurance of pain was reported by patients at the latest follow-up compared to pre-
operatively (p=0.05) and significantly more catching and locking sensations were reported at 
both the first annual review and latest follow-up (p=0.004 and p=0.019 respectively).   
 
Figure 3  
Box and whisker plots comparing Lysholm scores for different donor sites pre-operatively 
(A), at first annual review (B) and at latest follow-up (C).  Lysholm scores were not 
significantly different from each other pre-operatively or at first annual review, but at the 
latest follow-up, the Lysholm score of patients who had chondral harvest from the 
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intercondylar notch, had significantly lower scores than patients with harvests taken from the 
central trochlea (**p=0.01) and the medial trochlea (*p=0.02).  Actual Lysholm scores for the 
lateral condyle at the three time points are represented as small crosses.  The box and the 
horizontal line represent the interquartile range (IQR) and the median respectively.  Outliers 
are represented as a small triangle. 
 
Figure 4 
Representative arthroscopic image of the donor site in a patient 11 months post-cell 
implantation for ACI of the knee.  The white portion in the centre of the image (black arrow) 
is the repaired cartilage in the centre of the trochlea, observed to be smooth and well 
integrated into the surrounding cartilage.   
 
Figure 5 
Representative histological images of a full depth repair tissue biopsy from the donor site in 
a patient 11 months post-cell implantation for ACI of the knee, stained with H&E (A) and TB 
(B).  Histological analysis of the repair cartilage demonstrated good matrix metachromasia 
(B) and good integration into the subchondral bone (C, higher powered image of dashed-line 
box region in A).  Polarised light revealed a mixture of hyaline cartilage and fibrocartilage (D, 
polarised image of C, f=fibrocartilage, h=hyaline cartilage, b=bone) also well integrated with 
each other.  All biopsies demonstrated a good surface (E, higher power image of the solid 
line box region in A).  Immunohistochemistry of sections demonstrate the widespread 
presence of type I collagen (F) but more restricted type II collagen in the lower region (G). 
Scale bars represent 500µm (A-B, F-G) and 250µm (C-E). 
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Table 1 
Classification of Lysholm scores pre-operatively, at first annual review and latest 
follow-up. 
 Excellent 
(95-100) 
Good 
(84-94) 
Fair 
(65-83) 
Poor 
(<64) 
Pre-op 72% 17% 5.5% 5.5% 
First annual review 42% 37% 21% - 
Latest follow-up 33% 22% 39% 5.5% 
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